What are the pharmacotherapy options for treating venous thromboembolism in cancer patients?

Author： Prandoni Paolo Piovella Chiara Filippi Lucia Vedovetto Valentina Dalla Valle Fabio Piccioli Andrea

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.15, Iss.6, 2014-04, pp. : 799-807

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Long-Term Therapy of Venous Thromboembolism in Cancer Patients

By Streiff Michael B.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 9, 2006-10 ,pp. : 903-910

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995-2011

By Ording Anne G. Horváth-Puhó Erzsébet Lash Timothy L. Ehrenstein Vera Borre Michael Vyberg Mogens Sørensen Henrik T.

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3692-3699

Blackwell Publishing

Access to resources Recommend Favorite

Treatment of thromboembolism in cancer patients

By Panova-Noeva Marina Falanga Anna

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 12, 2010-08 ,pp. : 2049-2058

Informa Healthcare

Access to resources Recommend Favorite

Dermatan Sulfate versus Unfractionated Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Surgery for Cancer: A Cost-Effectiveness Analysis

By Attanasio E.

PharmacoEconomics, Vol. 19, Iss. 1, 2001-01 ,pp. : 57-68

Adis International

Access to resources Recommend Favorite

Oncologists in northern England rarely prescribe prophylaxis for venous thromboembolism (VTE) among patients undergoing cancer treatment

Inpharma, Vol. 1, Iss. 1405, 2003-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite